MICROPORT SCIENTIFIC CORPORATION Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
MicroPort Scientific Corporation微創醫療科學有限公司 *
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 00853)
VOLUNTARY ANNOUNCEMENT CE APPROVAL OF FIREHAWK
Reference is made to the announcement of MicroPort Scientific Corporation (the "Company", together with its subsidiaries, the "Group") dated 28 January 2014 (the "Announcement") in relation to, among others, the submission of Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk") for ConformitéEuropéenne ("CE") approval. Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as defined in the Announcement.
This is a voluntary announcement made by the Company.
The board (the "Board") of directors (the "Directors") of the Company is pleased to announce that on 23 January 2015, Firehawk received the CE mark approval.
The CE approval of Firehawk provides the preconditions for the Group to penetrate the European drug-eluting stents ("DES") markets with the sale of Firehawk in the European Economic Area, which will further propel the Group towards becoming a global medical device provider.
Firehawk is the Company's third generation, internally developed DES, following FireBird and FireBird2, for the treatment of coronary artery stenosis and occlusion, which was first approved for the People's Republic of China by the China Food and Drug Administration in January 2014, and is currently being widely used in the People's Republic of China for the treatment of coronary artery disease.
1
By order of the Board MicroPort Scientific Corporation Dr. Zhaohua Chang
Chairman
Shanghai, the People's Republic of China, 26 January 2015
As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Mr. Hiroshi Shirafuji and Ms. Weiwei Chen; and the independent non-executive Directors are Mr. Zezhao Hua, Mr. Jonathan H. Chou and Dr. Guoen Liu.
* for identification purpose only
2
|
distributed by
|
